Literature DB >> 23034171

Reconstitution of protective immune responses against cytomegalovirus and varicella zoster virus does not require disease development in pediatric recipients of umbilical cord blood transplantation.

Natacha Merindol1, Insaf Salem Fourati, Rose-Marie Brito, Anne-Julie Grenier, Emily Charrier, Paulo Cordeiro, Martine Caty, Samira Mezziani, Brigitte Malette, Michel Duval, Carolina Alfieri, Philippe Ovetchkine, Françoise Le Deist, Hugo Soudeyns.   

Abstract

CMV and varicella zoster virus (VZV) are significant causes of morbidity and mortality following umbilical cord blood transplantation (UCBT). However, the kinetics of reconstitution and protective potential of antiviral cell-mediated immune responses following UCBT remain poorly characterized. In this study, the reconstitution of CMV- and VZV-specific T cell responses was assessed using IFN-γ ELISPOT in 28 children who underwent UCBT to treat hematological or inherited disorders. Barely detectable in the first 3 mo posttransplantation, CMV- and VZV-specific T cell responses were observed in 30.4% and 40.3% of study subjects after 36 mo of follow-up. Four of five CMV-seropositive subjects developed detectable levels of circulating CMV DNA (DNAemia), and 5 of 17 VZV-seropositive patients experienced herpes zoster during the posttransplant period. Four CMV-seronegative subjects developed IFN-γ responses against CMV, and four subjects developed a VZV-specific IFN-γ response without clinical signs of infection. No CMV- or VZV-related events were observed in study subjects following the development of CMV- or VZV-specific responses > 150 spot-forming units/10(6) PBMCs, consistent with T cell-mediated protection. Finally, famciclovir prophylaxis did not strictly prevent the reconstitution of the VZV-specific T cell repertoire, because the frequency of T cells producing IFN-γ in response to VZV Ags reached levels consistent with protection in two nonzoster subjects. Monitoring of CMV- and VZV-specific cell-mediated immunity could inform immunocompetence and guide the initiation and cessation of antiherpetic prophylaxis in UCBT recipients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23034171     DOI: 10.4049/jimmunol.1201759

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Development of an IFN-γ ELISpot assay to assess varicella-zoster virus-specific cell-mediated immunity following umbilical cord blood transplantation.

Authors:  Insaf Salem Fourati; Anne-Julie Grenier; Élyse Jolette; Natacha Merindol; Philippe Ovetchkine; Hugo Soudeyns
Journal:  J Vis Exp       Date:  2014-07-09       Impact factor: 1.355

2.  Patient risk stratification and tailored clinical management of post-transplant CMV-, EBV-, and BKV-infections by monitoring virus-specific T-cell immunity.

Authors:  Anastasia Papadopoulou; Kiriakos Koukoulias; Maria Alvanou; Vassilios K Papadopoulos; Zoe Bousiou; Vasiliki Kalaitzidou; Fotini S Kika; Apostolia Papalexandri; Despina Mallouri; Ioannis Batsis; Ioanna Sakellari; Achilles Anagnostopoulos; Evangelia Yannaki
Journal:  EJHaem       Date:  2021-06-01

Review 3.  Improving engraftment and immune reconstitution in umbilical cord blood transplantation.

Authors:  Robert Danby; Vanderson Rocha
Journal:  Front Immunol       Date:  2014-02-24       Impact factor: 7.561

4.  Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.

Authors:  Euri Seo; Eun Seok Choi; Jung Hwa Kim; Hyery Kim; Kyung-Nam Koh; Ho Joon Im; Jina Lee
Journal:  PLoS One       Date:  2021-02-05       Impact factor: 3.240

5.  A Simple-to-Perform ifn-γ mRNA Gene Expression Assay on Whole Blood Accurately Appraises Varicella Zoster Virus-Specific Cell-Mediated Immunity After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Mathilde Boccard; Anne Conrad; William Mouton; Florent Valour; Chantal Roure-Sobas; Emilie Frobert; Barbara Rohmer; Vincent Alcazer; Hélène Labussière-Wallet; Hervé Ghesquières; Fabienne Venet; Karen Brengel-Pesce; Sophie Trouillet-Assant; Florence Ader
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

Review 6.  The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.

Authors:  Francesco Saglio; Patrick J Hanley; Catherine M Bollard
Journal:  Cytotherapy       Date:  2014-02       Impact factor: 5.414

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.